| Reactions | Indication | | ROR (95% CI) | PRR (95% CI, ) | BCPNN (IC-2SD) | EBGM (EBGM05) |
| Melaena | Prophylaxis | 101 | 1.55 (1.28, 1.89) | 1.55 (1.35, 1.75, 19.08) | 0.62 (0.6) | 1.55 (1.38) | Duodenal ulcer | Prophylaxis | 48 | 2.29 (1.72, 3.04) | 2.29 (2.01, 2.57, 33.38) | 1.15 (1.11) | 2.28 (2.04) | Gastritis erosive | Prophylaxis | 46 | 3.29 (2.46, 4.4) | 3.29 (3, 3.58, 70.1) | 1.64 (1.59) | 3.26 (3.02) | Gastric ulcer hemorrhage | Prophylaxis | 42 | 2.29 (1.69, 3.11) | 2.29 (1.99, 2.6, 29.16) | 1.15 (1.11) | 2.28 (2.03) | Blood loss anemia | Prophylaxis | 33 | 1.54 (1.09, 2.16) | 1.54 (1.2, 1.88, 5.63) | 0.59 (0.56) | 1.53 (1.25) | Duodenal ulcer hemorrhage | Prophylaxis | 21 | 2.06 (1.34, 3.16) | 2.06 (1.63, 2.49, 10.29) | 0.97 (0.91) | 2.05 (1.69) | Dyspnoea at rest | Prophylaxis | 13 | 1.78 (1.03, 3.07) | 1.78 (1.24, 2.33, 3.69) | 0.75 (0.69) | 1.78 (1.32) | Urinary tract discomfort | Prophylaxis | 9 | 13.46 (6.9, 26.25) | 13.46 (12.79, 14.13, 87.65) | 2.56 (2.35) | 12.91 (12.35) | Erosive duodenitis | Prophylaxis | 7 | 2.43 (1.15, 5.1) | 2.43 (1.68, 3.17, 4.48) | 1.04 (0.94) | 2.41 (1.79) | Naevus flammeus | Prophylaxis | 5 | 8.1 (3.33, 19.69) | 8.1 (7.21, 8.99, 23.73) | 1.87 (1.66) | 7.91 (7.16) | Total | | 325 | | | | |
|
|